Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

NCT04179084 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT04179084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04179084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 28, 2019
Completion date
May 1, 2020
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastasis colorectal cancer